The global age-related macular degeneration therapeutics market is expected to grow at a significant CAGR during the forecast period (2021-2027). Age-related macular degeneration (AMD), commonly known as macular degeneration, is a disorder in which the macula of the retina thins, resulting in loss of central vision. Age-related macular degeneration is most common in the elderly population and can result in permanent visual loss in those aged 60 and up.

Dry age-related macular degeneration (Dry AMD) and wet age-related macular degeneration (Wet AMD) are the two kinds of age-related macular degeneration (wet AMD). Dry age-related macular degeneration is the most prevalent type of macular degeneration, in which the macula thins with age and central vision is lost. Dry age-related macular degeneration does not have a treatment. The less prevalent variety of age-related macular degeneration is wet age-related macular degeneration, which is marked by the proliferation of aberrant blood vessels behind the retina. Anti-vascular endothelial growth factor (anti-VEGF) injections can be used to treat wet age-related macular degeneration. 

During the forecast period, the global age-related macular degeneration therapeutics market is expected to be driven by an increase in the geriatric population. According to the World Population Prospects report from 2017, the global population over 60 years old was 962 million, with a projected increase to roughly 2.1 billion by 2050. Globally, the population of people aged 60 and over is growing at a greater rate than all other age categories. This population is particularly vulnerable to age-related disorders such as diabetes, renal insufficiency, arthritis, and macular degeneration. People between the ages of 50 and 59 have a 2% chance of developing advanced age-related macular degeneration, however, those above the age of 75 have a 30% chance. Therefore, the rising prevalence of age-related macular degeneration is expected to boost the market growth.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Novartis International AG, Bayer AG, Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd. Pfizer Inc., Amgen Inc among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Age-Related Macular Degeneration Therapeutics Market Report Segmentation

By Type

• Dry Age-Related Macular Degeneration

• Wet Age-Related Macular Degeneration

By Distribution Channel 

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

By Drug Type 

• Brolucizumab

• Bevacizumab

• Ranibizumab

• Pegaptanib

• Aflibercept

• Others

Global Age-Related Macular Degeneration Therapeutics Market by Region